Journal of
Clinical Medicine and Research

  • Abbreviation: J. Clin. Med. Res.
  • Language: English
  • ISSN: 2141-2235
  • DOI: 10.5897/JCMR
  • Start Year: 2009
  • Published Articles: 106

Full Length Research Paper

Comparative in vitro potency of four fluoroquinolones on clinical isolates over a year period

Oyinloye J. M. Adedeji
  • Oyinloye J. M. Adedeji
  • Department of Biological Sciences, Afe Babalola University Ado Ekiti, Nigeria.
  • Google Scholar
Otuneme Oluchi
  • Otuneme Oluchi
  • Department of Biosciences and Biotechnology, Babcock University, Nigeria.
  • Google Scholar
Akeredolu A. A.
  • Akeredolu A. A.
  • Department of Biosciences and Biotechnology, Babcock University, Nigeria.
  • Google Scholar
Ezekiel C. N.
  • Ezekiel C. N.
  • Department of Biosciences and Biotechnology, Babcock University, Nigeria.
  • Google Scholar
Babalola B. Teniola
  • Babalola B. Teniola
  • Department of Mathematical and Physical Sciences, Afe Babalola University Ado Ekiti, Nigeria.
  • Google Scholar
Obebe Olusola O.
  • Obebe Olusola O.
  • Department of Veterinary Microbiology and Parasitology, University of Ibadan, Ibadan, Oyo State Nigeria.
  • Google Scholar
Nwadike Faith U.
  • Nwadike Faith U.
  • Department of Biosciences and Biotechnology, Babcock University, Nigeria.
  • Google Scholar
Alatise Folasade A.
  • Alatise Folasade A.
  • Department of Biosciences and Biotechnology, Babcock University, Nigeria.
  • Google Scholar


  •  Accepted: 16 December 2013
  •  Published: 31 January 2014

References

Acar JF, Goldstein FW (1997). "Trends in bacterial resistance to fluoroquinolones," Clin. Infect. Dis. 24(1):S67–S73.
Crossref
 
Adam HJ, Hoban DJ, Gin AS, Zhanel GG (2009). "Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997–2006," Int. J. Antimicrob. Agents 34(1):82-5.
Crossref
 
AMR Trends Report Epidemiological services (2009). British Columbia Centre for Disease Control, "Antimicrobial resistance trends in the province of British Columbia," AMR Trends Report. View
 
Azap OK, Arslan H, Serefhanog lu K, Colakog lu S, Erdogan H, Timurkaynak F, Senger SS (2010). "Risk factors for extended-spectrum β-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections," Clin. Microbiol. Infect. 16(2):147–151.
Crossref
 
Bhanot SK, Singh M, Chatterjee NR (2001). The Chemical and Biological Aspects of Fluoroquinolones: Reality and Dreams. Current Pharmaceutical Design, 7:313-337.
Crossref
 
Bhavnani SM, Hammel JP, Jones RN, Ambrose PG (2005). "Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States, "Diagnostic Microbiol. Infect. Dis. 51(1):31–37.
Crossref
 
Burns JL, Saiman L, Whittier S, Larone D, Krzewinski J, Liu Z, Marshall SA, Jones RN (2000). "Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients," J. Clin. Microbiol. 38(5):1818–1822.
Pubmed
 
Urban C, Naim R, Xilin Z, Noriel M, Sorana Segal-Maurer, Karl D, James JR (2001). "Fluoroquinolone resistant Streptococcus pneumoniae associated with levofloxacin therapy," J. Infect. Dis. 184(6):794–798.
Crossref
 
Chen DK, McGeer A, De Azavedo JC, Low DE (1999). "Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada," New Engl. J. Med. 341(4):233–229.
Crossref
 
Han C, Yang Y, Wang M, Wang A, Lu Q, Xu X, Wang C, Liu L, Deng Q, Shen X (2010). "The prevalence of plasmidmediated quinolone resistance determinants among clinical isolates of ESBL or AmpC-producing Escherichia coli from Chinese pediatric patients," Microbiol. Immunol. 54(3):123–128.
Crossref
 
Chikwendu CI, Nwabueze RN, Anyanwu BN (2008). Antibiotic resistance profile of Escherichia coli from clinically healthy pigs and their commercial farm environments. Afr. J. Microbiol. Res. 2:12 – 17.
 
Clinical and Laboratory Standards Institute, CLSI (2006). Performance standards for antimicrobial susceptibility testing, 16th informational supplement. M100-S16, Vol. 26, No. 3, pp: 1–37. 
 
Cowan SR, Stell KJ (1993). Manual for Identification of Medical Bacteria, pp. 140–143. 3rd Ed. Cambridge University Press, Uk.
 
Foroumadi A, Ghodshi S, Emani S, Najjari S, Samadi N, Ali Faramarzi M, Beikmohammadi L, Shirazi FH, Shafie A (2006). Synthesis and antibacterial activity of new fluoroquinolones containing a substituted N-(phenethyl) piperzine moiety. Bioorg. Med. Chem. Lett, 16:3499-3503.
Crossref
 
Fuller JD, Low DE (2005). "A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance," Clin. Infect. Dis. 41(1):118–121.
Crossref
 
Manno G, Cruciani M, Romano L, Scapolan S, Mentasti M, Lorini R, Minicucci L (2005). "Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre," Int. J. Antimicrobial Agents 25(3):193–197.
Crossref
 
Ho PL, Que TL, Tsang DNC, Ng TK, Chow KH, Seto WH (1999). "Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumonia in Hong Kong," Antimicrob. Agents Chemother. 43(5):1310–1313.
Pubmed
 
Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF (2002). "Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States," Antimicrob. Agents Chemother. 46(8):2540–2545.
Crossref
 
Lehn N, StöwerHoffmann J, Kott T, Strassner C, Wagner H, Krönke M, Schneider-Brachert W (1996). Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance. J Clin Microbiol. 34:597-602.
Pubmed
 
Luzzaro F (2008). Fluoroquinolones and Gram-negative bacteria: antimicrobial activity and mechanisms of resistance. Le Infezioni in Medicina, 16(2):5–11.
Pubmed
 
Morosini MI, Garc´Ä±a-Castillo M, Loza E, P´erez-V´azquez M, Baquero F, Cant´on R (2005), "Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips," J. Clin. Microbiol. 43(9):4480–4485.
Crossref
 
Mulvey MR, Simor AE (2009). Antimicrobial resistance in hospitals: How concerned should we be? Can. Med. Assoc. J. 180: 408–415.
Crossref
 
Naber KG, Schito G, Botto H, Palou J, Mazzei T (2008). "Surveillance Study in Europe and Brazil on Clinical Aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for Empiric Therapy. European Urology 54(5):1164–1178.
Pubmed
 
Neuzillet Y, Naber KG, Schito G, Gualco L, Botto H (2012). "French results of the ARESC Study: clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy," Medecine et Maladies Infect. 42(2):66–75
Crossref
 
Paterson DL (2004). "'Collateral damage"' from cephalosporin or quinolone antibiotic therapy," Clin. Infect. Dis. 38(4):S341–S345.
Crossref
 
Pitt TL, Sparrow M, Warner M, Stefanidou M (2003). "Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents," Thorax, 58(9):794–796.
Crossref
 
Pletz MW, van der Linden M, von Baum H, Duesberg CB, Klugman KP, Welte T (2011). "Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with communityacquired pneumonia despite high fluoroquinolone usage," Int. J. Med. Microbiol. 301(1):53–57.
Crossref
 
Pottumarthy S, Fritsche TR, Sader HS, Stilwell MG, Jones RN (2005). "Susceptibility patterns of Streptococcus pneumonia isolates in North America (2002–2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents," Int. J. Antimicrob. Agents 25(4):282–289.
Crossref
 
Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, Fleming C, Low DE (2002). "Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia," New Engl J. Med. 346(10):747–750.
Crossref
 
Schulin T (2002). "In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany," J. Antimicrob. Chemother. 49(2):403–406.
Crossref
 
Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A (2009). "The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections," Int. J. Antimicrob. Agents 34(5):407–413.
Pubmed
 
Schwartz B, Bell DM, Hughes JM (1997). Preventing the emergence of antimicrobial resistance: A call for action by clinicians, public health officials and patients. JAMA, 278:944–945.
Pubmed
 
Shindikar AV, Viswanthan CL (2005). Novel fluoroquinolones: design, synthesis and in vitro activity in mice against Mybacteririum tuberculosis H-37 Rv, Bioorg. Med. Chem. Lett. 15:1803-6.
Pubmed
 
Sibi G, Devi AP, Fouzia K, Patil BR (2011). Prevalence, microbiologic profile of urinary tract infection and its treatment with trimethoprim in diabetic patients. Res. J. Microbiol. 6:543–551.
Crossref
 
Smith DW (1999). Decreased antimicrobial resistance after changes in antibiotics use. Pharmacotherapy 19:129–132.
Crossref
 
Strateva T, Petrova G, Perenovska P, Mitov I (2009), "Bulgarian cystic fibrosis Pseudomonas aeruginosa isolates: antimicrobial susceptibility and neuraminidase-encoding gene distribution," J. Med. Microbiol. 58(5):690–692.
Crossref
 
Taddele MH, Rathore R, Dhama K (2012). Antibiogram assay of Salmonella gallinarum and other Salmonella enteric serovars of poultry origin in India. Asian J. Anim. Vet. Adv. 7:309–317.
Crossref
 
Talah A, Gadad K (2006). Synthesis, antibacterial and antitubercular activities of some7-[4-(5-amino-[1, 3, 4] thiadiazole-2-sulfonyl)-piperazin-1-yl] fluoroquinolonic derivatives. Eur. J. Med. Chem. 1-7. Pubmed
 
Truong QC, Gutmann L, Shlaes D, Moreau NJ (1995). New mutation in DNA gyrase of Escherichia coli conferring resistance to quinolones [abstract no. C61]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy.
 
Wagenlehner FME, Schmiemann G, Hoyme U, Fünfstück R, Hummers-Pradier E, Kaase M, Kniehl E, Selbach I, Sester U, Vahlensieck W, Watermann D, Naber KG (2011). "National S3 guideline on uncomplicated urinary tract infection: recommendations for treatment and management of uncomplicated community-acquired bacterial urinary tract infections in adult patients," Urologe A, 50(2):153–169.
Crossref
 
Waites K, Brown S (2003). "Antimicrobial resistance among isolates of respiratory tract infection pathogens from the southern United States: data from the PROTEKT US surveillance program 2000/2001." Southern Med. J. 96(10):974–985.
Pubmed